Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in pancreatic cancer patients.

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

DZD8586 achieved a high response rate in patients with relapsed/refractory CLL/SLL.

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with high-risk neuroblastoma.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in progressive desmoid tumors.

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with metastatic melanoma.

Catch up on the week's latest oncology news, from clinical trial updates to FDA approvals.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.